Vasodilators for Acute Heart Failure — A Systematic Review with Meta-Analysis
Jasmin Dam Lukoschewitz, Kristina Miger, Anne Sophie Overgaard Olesen, Nora Olsen El Caidi, Caroline Barkholt Kamp, Olav Wendelboe Nielsen, Christian Hassager, Jens Dahlgaard Hove, Ekim Seven, Jacob Eifer Møller, Janus Christian Jakobsen, Johannes Grand
Abstract
BACKGROUND: Acute heart failure is a public health concern. This study systematically reviewed randomized clinical trials (RCTs) to evaluate vasodilators in acute heart failure. METHODS: The search was conducted across the databases of Medline, Embase, Latin American and the Caribbean Literature on Health Sciences, Web of Science, and the Cochrane Central Register of Controlled Trials. Inclusion criteria consisted of RCTs that compared vasodilators versus standard care, placebo, or cointerventions. The primary outcome was all-cause mortality; secondary outcomes were serious adverse events (SAEs), tracheal intubation, and length of hospital stay. Risk of bias was assessed in all trials. RESULTS: =51.96%) compared with no receipt of vasodilators. CONCLUSIONS: In this systematic review with meta-analysis of patients with acute heart failure, vasodilators did not reduce all-cause mortality.